Sanhuang Shuangding Powder is supplied as a spray-dried or vacuum-dried multicomponent botanical API powder for downstream conversion into tablets, injections, capsules, powders, granules, premixes, and solutions. Two veterinary-grade API models are available: SHSD-P-VG-API-100 for injection-grade applications and SHSD-P-VG-API-200 for oral and feed-premix applications. The powder is standardised to HPLC marker compounds rather than to a single extraction solvent signature; the release basis comprises total anthraquinones, berberine hydrochloride, and baicalin, with representative limits of total anthraquinones not less than 1.0% w/w, berberine hydrochloride not less than 0.5% w/w, and baicalin not less than 2.0% w/w. Physical presentation is a brownish-yellow to brown hygroscopic powder with a bulk density of 0.35–0.55 g/mL and a tapped density of 0.50–0.75 g/mL. The injection-grade model is controlled to a particle-size distribution of D90 ≤ 30 µm, while the oral-grade model is controlled to D90 ≤ 180 µm. The product retains the natural botanical matrix; therefore, aqueous preparations are colloidal dispersions rather than true solutions, and this characteristic governs downstream filtration, filling, and sterilisation choices.

Drying, particle engineering, and the injection-grade dissolution envelope

Process data from production-scale spray drying on a 200 L rotary-atomiser dryer with inlet air at 160–170 °C and outlet temperature maintained at 70–75 °C indicate that the moisture endpoint is sensitive to outlet air temperature. Above 75 °C, the marker compounds baicalin and berberine hydrochloride show HPLC area losses exceeding 2–3% relative to the input extract solids; below 68 °C, residual moisture rises above 5.0% w/w and powder caking occurs on the cyclone wall. The spray-dried powder exhibits an onset glass transition near 55 °C by modulated differential scanning calorimetry; therefore, milling and sieving are performed with nitrogen cooling to keep the powder below 45 °C. The injection-grade model is further processed through a spiral jet mill with nitrogen cooling to achieve D90 ≤ 30 µm. The milled powder is then sieved through an inline vibratory sieve with a 150 µm mesh for the oral model and a 45 µm mesh for the injection model. Bulk density after milling is maintained at 0.38–0.48 g/mL to support capsule filling and tablet die fill consistency. For aqueous reconstitution, the injection-grade powder is dispersed under high-shear mixing at 3000 rpm for 10 min; undissolved matrix solids are removed by centrifugation at 8000 rpm before sterile filtration. The resulting filtrate remains opalescent, and light obscuration testing should be used to confirm particulate matter limits for injectable finished products.

For dry premix and granule manufacture, the oral-grade powder is commonly adsorbed onto precipitated silica or maltodextrin at a ratio of 1:4 to 1:9 to reduce segregation and improve flow. In a 500 L ploughshare mixer run at 60 rpm for 10 min, blend uniformity values of ≤ 5.0% RSD are obtained when the API is pre-milled to D90 ≤ 180 µm; coarser material shows content uniformity failures in low-dose tablets where the API component is below 2.0% w/w of the tablet mass. Moisture uptake is a critical limit: the powder is hygroscopic and may gain 1.5–2.5% w/w moisture within 30 min at 25 °C and 60% RH. Therefore, open handling is limited to ≤ 30 min in non-conditioned cleanrooms; pre-drying is required when the powder is stored at RH > 60% or when the residual water by USP <921> exceeds 6.0% w/w. Wet granulation is performed with an aqueous binder solution containing polyvinylpyrrolidone at 3–5% w/w; the wet mass is dried in a fluid-bed dryer at inlet air temperature not exceeding 60 °C to avoid thermal marker loss. Granules for premix use are typically sized through a 1.0 mm screen and blended with ground corn cob or dextrose to a final API concentration of 0.1–1.0% w/w depending on the target species and dosing programme. Finished premixes are assayed after 10 random sampling points; acceptance is 90.0–110.0% of label claim with RSD ≤ 5.0%.

Why is a separate injection-grade specification necessary for this multi-herb API?

The injection-grade specification differs not only by particle size but by bacterial endotoxin, bioburden, and particulate matter controls. The oral-grade powder may carry a total aerobic microbial count of ≤ 1000 CFU/g and a combined yeast and mould count of ≤ 100 CFU/g when tested according to USP <61>; this is acceptable for dry oral dosage forms but is not acceptable for injection. The injection-grade model is controlled to ≤ 10 CFU/g total aerobic microbial count, and bacterial endotoxins are not more than 0.5 EU/mg by USP <85>. Terminal sterilisation of the finished solution is still required; the API is not sterilised as a dry powder in routine production. Particulate matter is controlled after reconstitution through a 0.45 µm clarifying filter and a 0.22 µm sterilising-grade membrane. The multi-herb matrix contains water-insoluble polysaccharides and tannins; therefore, the injection model is extracted through a sequence of ethanol precipitation, centrifugation at 8000 rpm, and membrane clarification to reduce insoluble solids before spray drying. Residual ethanol after drying is controlled under ICH Q3C at ≤ 5000 ppm; acetone and methanol are not used in the injection-grade extraction path.

When the spray-dried powder is directed to tablet compression, a 16-station rotary tablet press equipped with 8 mm round tooling is used. Blends containing the API at 5–30% w/w with microcrystalline cellulose and croscarmellose sodium compress at 8–15 kN to produce tablets with hardness 60–120 N and friability below 1.0% w/w by USP <1216>. Disintegration tested by USP <701> is ≤ 15 min in water at 37 °C for uncoated tablets. Because the powder contains hygroscopic botanical solids, prolonged dwell times above 20 ms at RH > 50% may cause picking on the upper punch face. Capsule filling on a dosator machine with size 0 capsules requires a minimum bulk density of 0.40 g/mL and a maximum angle of repose of 38°; when the powder is milled too fine, flow aids such as fumed silica at 0.5–1.0% w/w are necessary. Powder formulations for direct administration are adjusted to a target marker content through geometric dilution with dextrose or lactose; the final powder should be protected from light and moisture in unit-dose sachets.

Comparative differentiation against single-marker botanical powders and non-API feed-grade botanicals

Unlike non-API feed-grade botanical powders, this product is released under pharmacopoeial microbial, heavy metal, and marker-content controls and is supported by batch-specific certificates of analysis. Unlike single-compound synthetic APIs, the Sanhuang Shuangding Powder API is a multi-component matrix whose clinical effect, where described, derives from a defined marker profile rather than a single chemical entity. This difference influences analytical strategy: release testing requires simultaneous HPLC separation of anthraquinone, isoquinoline alkaloid, and flavone fractions with relative retention time matching against certified reference substances. For some single-marker equivalence studies, published data for this specific configuration is limited; therefore, formulation decisions should be confirmed by pilot-scale trials using the intended final dosage form.

If the powder is to be incorporated into injectable solutions, terminal sterilisation remains the critical control point

Steam sterilisation at 121 °C for 15 min is feasible only if the batch has been validated for pH stability and marker retention. The solution pH should be maintained between 5.5 and 6.8; above pH 7.5, berberine hydrochloride precipitates, and below pH 3.5, baicalin solubility decreases. In heat-sensitive formulations, aseptic processing through a 0.22 µm sterilising-grade polyethersulfone filter is used; filter compatibility studies show that nylon membranes may adsorb anthraquinones and should be avoided. The maximum holding time of the compounded solution before filtration is 4 h at 20–25 °C under nitrogen blanketing; longer holding times lead to visible particulate formation. The powder should not be dry-autoclaved, and it should not be blended with amine-based preservatives that can generate aldehydes under terminal heat. For injectable manufacturing, the API is reconstituted in water for injection at 20–25 °C, adjusted to pH 5.8–6.2, prefiltered through a 0.45 µm polypropylene cartridge, and then sterile-filtered into sterilised depyrogenated vials. Terminal sterilisation by autoclave is selected only when the finished solution remains within the marker-content specification after the cycle.

For all models, the primary packaging is a double polyethylene liner inside an aluminium foil laminate bag, with 25 kg net per drum. Storage is at ≤ 25 °C and ≤ 60% RH in a light-protected area; freezing is not recommended. The manufacturer’s retest period is 24 months for unopened oral-grade material and 18 months for injection-grade material. Once opened, the powder should be used within 30 days when stored under nitrogen. Avoid contact with strong oxidising agents, acidic materials that may hydrolyse flavonoid glycosides, and open handling during high-humidity seasons without dehumidification. If a batch exceeds the specified residual water limit of 6.0% w/w by USP <921>, re-drying at 50 °C under vacuum is permitted only for oral-grade material; injection-grade material should not be re-dried because of endotoxin redistribution and particle-surface changes. The packaging is not suitable for aseptic transfer; injection-grade material is subdivided into single-use gamma-sterilised pouches when required.